MedTrace Logo

Treatment of Advanced Renal Cell Carcinoma With Quinacrine

NCT00574483 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-03

No results posted yet for this study

Summary

The overall response to standard therapies and to the newer antiangiogenesis therapies is not curative, and treatment-associated toxicities may be severe. Therefore, continued evaluation of therapies, with different mechanisms of action, is needed for patients with metastatic RCC.

Conditions

Interventions

DRUG

quinacrine

100 mg day

Sponsors & Collaborators

  • Cleveland BioLabs

    lead INDUSTRY

Principal Investigators

  • John H Gordon, PhD · Cleveland BioLabs

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00574483 on ClinicalTrials.gov